Advertisement

Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics

  • Anne L. Kunkler
  • Elaine M. Binkley
  • Dimosthenis Mantopoulos
  • Andrew J. Hendershot
  • Matthew P. Ohr
  • Kari L. Kendra
  • Frederick H. Davidorf
  • Colleen M. CebullaEmail author
Oncology

Abstract

Purpose

Increases in cancer with an aging population and the rapid development of new chemotherapeutics underscore the need for ophthalmologists to identify and manage potential ocular toxicities. This retrospective case series reports the ocular side effects of traditional and novel chemotherapeutic agents from a large center.

Methods

The medical records of 3537 adult patients 18 years and older who presented to an academic ophthalmology department on high-risk medications identified by ICD-9 search between January 2010 and February 2015 were reviewed. A cancer diagnosis, as well as a temporal association with chemotherapeutic use and ocular side effect, was deemed necessary for inclusion in the study. The main measures were ocular side effects in cancer patients taking chemotherapy, ocular imaging abnormalities, and the outcome of each side effect.

Results

Of the 161 oncology patients referred to the ophthalmology clinic for chemotherapeutic screening or ocular side effect, 31 (19.3%) were identified as having an ocular adverse reaction due to a novel or traditional chemotherapeutic medication. A novel flattening of the corneal curvature with hyperopic shift and corneal microcysts was identified in a patient taking the antibody–drug conjugate mirvetuximab soravtansine and was reversible with topical steroids. A bilateral medium-vessel choroidal vasculopathy with serous retinal detachment was seen with ipilimumab. The most frequent medication with ocular toxicity was interferon-α(2b) (IFN-α(2b)) (6/31, 19.4%); headache was typical in these patients (83.3%). Ibrutinib ocular toxicity was second most common (5/31, 16.1%), usually causing red or dry eye, while one patient developed branch retinal artery occlusion. Retinal abnormalities documented on OCT imaging occurred with IFN-α(2b), ipilimumab, binimetinib, and docetaxel, while rod-cone ERG abnormality was seen with cisplatin. Inflammatory conditions included anterior scleritis with zoledronic acid, focal eyelid inflammation with veliparib, bilateral chemosis with R-CHOP, iritis, and blepharospasm with IFN-α(2b). AION occurred with pemetrexed, and transient vision loss with hyperemic disc OS was seen with FOLFOX. Two patients (2/31, 6.5%) developed permanent vision loss. Six patients were lost to follow-up, and the clinical course was unknown (6/31, 19.4%).

Conclusions and relevance

Cases of permanent visual loss were observed; yet, in the majority of side effects, they improved with topical therapy and/or holding the medication. Further research is needed to elucidate the incidence and the pathophysiology of these side effects and maximize patient quality of life.

Keywords

Ocular toxicity Targeted chemotherapy Systemic chemotherapy Cancer 

Notes

Acknowledgments

Nathaniel Dusseau and Rania Kusibati are acknowledged for the technical assistance.

Funding

This study was funded by the Ohio Lions Eye Research Foundation, National Eye Institute of the National Institutes of Health (K08EY022672), The Patti Blow Fund, and the Retina Research in Ophthalmology Fund (#313310).

Compliance with ethical standards

Conflict of interest

Anne Kunkler declares that she has no conflict of interest. Elaine M. Binkley declares that she has no conflict of interest. Dimosthenis Mantopoulos declares that he has no conflict of interest. Andrew J. Hendershot declares that he has no conflict of interest. Matthew P. Ohr declares that he has no conflict of interest. Kari L. Kendra declares that she has no conflict of interest. Frederick H. Davidorf declares that he has no conflict of interest. Colleen M. Cebulla declares that she has no conflict of interest.

Ethical approval

All research activities were in accordance with the ethical standards of the institutional review board committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The retrospective review was approved by the institutional review board committee.

Supplementary material

417_2019_4337_MOESM1_ESM.docx (18 kb)
Supplemental Table 1 Patient demographics and clinical presentation of ocular side effects with biologic agents. CWS, cotton wool spot; IVFA, intravenous fluorescein angiography; SD-OCT, spectral domain optical coherence tomography; ICG, indocyanine green angiography (DOCX 17 kb)
417_2019_4337_MOESM2_ESM.docx (14 kb)
Supplemental Table 2 Patient demographics and clinical presentation of ocular side effects with targeted therapies. OCT, optical coherence tomography; PEE, punctate epithelial erosions; NSCLC, non-small cell lung cancer; CLL, chronic lymphocytic leukemia; BRAO, branch retinal artery occlusion; CF, count fingers; OD, right eye; OS, left eye (DOCX 13 kb)
417_2019_4337_MOESM3_ESM.docx (17 kb)
Supplemental Table 3 Patient demographics and clinical presentation of ocular side effects with chemotherapeutic agents and supportive care. FOLFOX, folinic acid, fluorouracil, oxaliplatin; OS, left eye; FA, fluorescein angiography; R-CHOP, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone; PEE, punctate epithelial erosions; OU, both eyes; AION, anterior ischemic optic neuropathy; OD, right eye; R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin; ERG, electroretinogram; VEP, visual-evoked potentials; PRP, pan retinal photocoagulation; HAT, herceptin, avastin, taxotere (DOCX 17 kb)

References

  1. 1.
    DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653CrossRefPubMedGoogle Scholar
  2. 2.
    Schmid KE, Kornek GV, Scheithauer W, Binder S (2006) Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 51(1):19–40CrossRefPubMedGoogle Scholar
  3. 3.
    Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, Marmor MF et al (2014) Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 34(7):1261–1280CrossRefPubMedGoogle Scholar
  4. 4.
    Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S et al (2014) Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer 50(3):638–648CrossRefPubMedGoogle Scholar
  5. 5.
    Ho WL, Wong H, Yau T (2013) The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 91(7):604–609CrossRefPubMedGoogle Scholar
  6. 6.
    Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7:69–77CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL (2012) Ocular toxicity of targeted therapies. J Clin Oncol 30(26):3277–3286CrossRefPubMedGoogle Scholar
  8. 8.
    Fu C, Gombos DS, Lee J et al (2017) Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 8(35):58709–58727PubMedPubMedCentralGoogle Scholar
  9. 9.
    Mantopoulos D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133(8):965–967CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Turner LD, Harrison JD (2013) Bilateral optic disc edema and associated optic neuropathy in the setting of FOLFOX chemotherapy. BMC Ophthalmol 13:42CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wilding G, Caruso R, Lawrence TS et al (1985) Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 3(12):1683–1689CrossRefPubMedGoogle Scholar
  12. 12.
    Marmor MF (1993) Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 84:237–246CrossRefPubMedGoogle Scholar
  13. 13.
    Monzon JG, Hammad N, Stevens SD, Dancey J (2012) Retinopathy associated with adjuvant high-dose interferon-a2b in a patient with resected melanoma: a case report and review of the literature. Oncologist 17:384–387CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Patti F, Nicoletti A, Pappalardo A, Castiglione A, Lo Fermo S, Messina S et al (2012) Frequency and severity of headache is worsened by interferon-β therapy in patients with multiple sclerosis. Acta Neurol Scand 125(2):91–95CrossRefPubMedGoogle Scholar
  15. 15.
    Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib verses ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Niro A, Strippoli S, Alessio G et al (2015) Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase inhibitors: a case series. Am J Ophthalmol 160(5):959–967.e1CrossRefPubMedGoogle Scholar
  18. 18.
    Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM et al (2017) Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124(12):1788–1798CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ishii T, Iwasawa S, Kurimoto R, Maeda A, Takiguchi Y, Kaneda M (2015) Crizotinib-induced abnormal signal processing in the retina. PLoS One 10(8):e0135521CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hickson S, Papas E (1997) Prevalence of idiopathic corneal anomalies in a non contact lens-wearing population. Optom Vis Sci 74:293–297CrossRefPubMedGoogle Scholar
  21. 21.
    Humphreys JA, Larke JR, Parrish ST (1980) Microepithelial cysts observed in extended contact-lens wearing subjects. Br J Ophthalmol 64(12):888–889CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Moore KN, Martin LP, O’Malley DM et al (2017) Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol 35(10):1112–1118CrossRefPubMedGoogle Scholar
  23. 23.
    Jwaka J, Boddu S, Paturi DK, Shah S, Smith SB, Pal D, Mitra AK (2011) Functional characterization of folate transport proteins in Staten’s seruminstitut rabbit corneal epithelial cell line. Curr Eye Res 36(5):404–416CrossRefGoogle Scholar
  24. 24.
    Eaton JS, Miller PE, Mannis MJ, Murphy CJ (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31(10):589–604CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Anne L. Kunkler
    • 1
  • Elaine M. Binkley
    • 1
  • Dimosthenis Mantopoulos
    • 1
  • Andrew J. Hendershot
    • 1
  • Matthew P. Ohr
    • 1
  • Kari L. Kendra
    • 2
  • Frederick H. Davidorf
    • 1
  • Colleen M. Cebulla
    • 1
    Email author
  1. 1.Department of Ophthalmology and Visual Science, Havener Eye InstituteThe Ohio State University, Wexner Medical CenterColumbusUSA
  2. 2.Department of Internal Medicine, Division of Medical OncologyThe Ohio State University, Wexner Medical CenterColumbusUSA

Personalised recommendations